Loading…
Vivos Therapeutics, Inc. is projected to rise to $0.5413 by 2027, a +29% move from its current price of $0.4206. VVOS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.4035 | $0.4207 | $0.4387 | +0.03% |
| Aug 6 | $0.3967 | $0.4208 | $0.4464 | +0.05% |
| Aug 7 | $0.3915 | $0.4209 | $0.4525 | +0.08% |
| Aug 8 | $0.3873 | $0.421 | $0.4577 | +0.11% |
| Aug 9 | $0.3836 | $0.4212 | $0.4624 | +0.13% |
| Aug 10 | $0.3803 | $0.4213 | $0.4667 | +0.16% |
| Aug 11 | $0.3773 | $0.4214 | $0.4706 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3773 | $0.4214 | $0.4706 | +0.18% |
| Week 2 | $0.361 | $0.4222 | $0.4936 | +0.37% |
| Week 3 | $0.3492 | $0.4229 | $0.5122 | +0.55% |
| Week 4 | $0.3396 | $0.4237 | $0.5286 | +0.74% |
| Week 5 | $0.3315 | $0.4245 | $0.5435 | +0.92% |
| Week 6 | $0.3244 | $0.4253 | $0.5575 | +1.11% |
| Week 7 | $0.318 | $0.4261 | $0.5708 | +1.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
The company also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado, and it was formerly known as Vivos BioTechnologies, Inc., changing its name to Vivos Therapeutics, Inc.
in March 2018.
VVOS is the stock ticker for Vivos Therapeutics, Inc., a healthcare company focused on dentofacial abnormalities, obstructive sleep apnea, and snoring. It is currently priced at $0.42 per share with a market capitalization of $5.84M and a global ranking of 5007 by market cap. The current price positioning places VVOS as a micro-cap with notable volatility and a narrow near-term trading range.
A major floor 22.8% below — a decisive break under it would weaken the trend.
The nearest floor, 7.0% below — buyers have tended to step in here.
The nearest ceiling, 18.9% above — a clean break opens room to run.
A major ceiling 249.5% above — clearing it would confirm fresh momentum.
Key VVOS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VVOS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4106 | Buy | $0.4091 | Buy |
| MA 10 | $0.4067 | Buy | $0.4115 | Buy |
| MA 20 | $0.4241 | Sell | $0.4304 | Sell |
| MA 50 | $0.5226 | Sell | $0.5438 | Sell |
| MA 100 | $0.778 | Sell | $0.8231 | Sell |
| MA 200 | $1.43 | Sell | $1.40 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.29 | Neutral |
| Stoch RSI (14) | 81.67 | Sell |
| CCI (20) | -43.03 | Neutral |
| Williams %R (14) | -34.48 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -0.73 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 65.52 | Neutral |
| TRIX (15) | -1.20 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 51.60 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 0.41 | Buy |
| ADX (14) | 23.97 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture shows neutral sentiment with RSI14 at 40, indicating modest momentum. The stock trades below the SMA50 of $0.5463 and well below the SMA200 of $1.50, suggesting near-term softness relative to the longer-term trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.391 | $0.4206 | $0.5413 | 0% | Neutral | |
| $0.411 | $0.5413 | $0.7647 | +29% | Bullish | |
| $0.3864 | $0.5327 | $0.7941 | +27% | Bullish | |
| $0.3715 | $0.5322 | $0.8267 | +27% | Bullish | |
| $0.3485 | $0.5168 | $0.8306 | +23% | Bullish | |
| $0.3129 | $0.479 | $0.7929 | +14% | Neutral | |
| $0.3147 | $0.4963 | $0.8434 | +18% | Neutral | |
| $0.3696 | $0.5997 | $1.04 | +43% | Bullish | |
| $0.4204 | $0.701 | $1.25 | +67% | Bullish | |
| $0.3973 | $0.68 | $1.23 | +62% | Bullish | |
| $0.4736 | $0.9173 | $1.81 | +118% | Bullish | |
| $0.5529 | $1.23 | $2.72 | +192% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.391 | $0.4206 | $0.4876 | +0.00% |
| September 2026 | $0.3431 | $0.4119 | $0.5126 | -2.08% |
| October 2026 | $0.355 | $0.4308 | $0.5449 | +4.60% |
| November 2026 | $0.3427 | $0.4196 | $0.5376 | -2.61% |
| December 2026 | $0.3384 | $0.4176 | $0.5413 | -0.47% |
Click any year to see its month-by-month VVOS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, VVOS could reach as high as $0.5413, with a base case around $0.4206 and support toward $0.391 — roughly 0% from $0.4206. A consolidation phase looks the most probable path here.
Expect VVOS to range from $0.411 to $0.7647 through 2027. The $0.5413 average target implies a +29% move from current prices. That is up +29% on the projected 2026 average. Momentum favours further upside here.
The VVOS price prediction for 2028 points to an average of $0.5327 (low $0.3864, high $0.7941) — a potential gain of +27% on today's $0.4206. Buyers look set to stay in control over this stretch.
In 2029, VVOS is projected to trade between $0.3715 and $0.8267, averaging $0.5322 — a potential gain of +27% from today's $0.4206. That is 0% versus the projected 2028 average. Momentum favours further upside here.
Vivos Therapeutics, Inc.'s 2030 outlook centres on $0.5168, within a $0.3485 to $0.8306 range. That is -3% versus the projected 2029 average. That marks a +23% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, VVOS could reach as high as $0.7929, with a base case around $0.479 and support toward $0.3129 — roughly +14% from $0.4206. Price action looks broadly range-bound.
Expect VVOS to range from $0.3147 to $0.8434 through 2032. The $0.4963 average target implies a +18% move from current prices. That is up +4% on the projected 2031 average. A consolidation phase looks the most probable path here.
The VVOS price prediction for 2033 points to an average of $0.5997 (low $0.3696, high $1.04) — a potential gain of +43% on today's $0.4206. Momentum favours further upside here.
In 2034, VVOS is projected to trade between $0.4204 and $1.25, averaging $0.701 — a potential gain of +67% from today's $0.4206. That is up +17% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Vivos Therapeutics, Inc.'s 2035 outlook centres on $0.68, within a $0.3973 to $1.23 range. That is -3% versus the projected 2034 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2040, VVOS could reach as high as $1.81, with a base case around $0.9173 and support toward $0.4736 — roughly +118% from $0.4206. Buyers look set to stay in control over this stretch.
Expect VVOS to range from $0.5529 to $2.72 through 2050. The $1.23 average target implies a +192% move from current prices. That is up +34% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in VVOS today (≈ 2,377.555873 VVOS) could be worth
$2,921.01
+$1,921.01 (+192%) by 2050 · US Dollar
Based on the average projected VVOS price of $1.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VVOSwould be worth at today's price.
$1,000 invested in VVOS on Jul 31, 2025 (≈ 230.946886 VVOS) would be worth
$97.14
-$902.86 (-90.3%) today · 0.10× · US Dollar
Based on a VVOS entry price of $4.33 vs. today's $0.4206.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.393 | $1,070.23 | +7.0% |
| 1 month ago | $0.498 | $844.58 | -15.5% |
| 3 months ago | $0.807 | $521.19 | -47.9% |
| 6 months ago | $1.62 | $259.63 | -74.0% |
| 1 year ago | $4.33 | $97.14 | -90.3% |
| All time (5.0y) ago | $67.88 | $6.2 | -99.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VVOS forecast.
Our base-case forecast reaches $0.84 around 2040.
Implied market cap at $0.84: $11.67M
The multi-year forecast projects a bullish drift in many years, with 2027 (avg $0.5621; ROI 33.8%), 2028 (avg $0.5382; ROI 28.1%), 2029 (avg $0.5474; ROI 30.3%), and 2030 (avg $0.5284; ROI 25.8%). The outlook remains bullish through 2033 (avg $0.6175; max $1.12; ROI 47%), 2034 (avg $0.7182; max $1.34; ROI 71%), and 2035 (avg $0.7017; max $1.34; ROI 67.1%), with stronger upside continuing in 2040 (avg $0.9372; max $1.95; ROI 123.1%) and 2050 (avg $1.25; max $2.87; ROI 196.9%). These estimates imply meaningful upside potential relative to the current price, but they are not guarantees and are sensitive to market conditions and company fundamentals.
Tap a question to reveal the answer.
2030 forecast: min $0.3418, avg $0.5284, max $0.8825; ROI 25.8%. Sentiment: BULLISH.
Forecasts show bullish sentiment in multiple years (2027, 2028, 2029, 2030, 2033-2035, 2040, 2050) with ROIs ranging from 11.5% to 196.9% in the stated years, though these are estimates and not guarantees.
Yes. The max forecast price exceeds $1 in several years: 2033 max $1.12, 2034 max $1.34, 2040 max $1.95, and 2050 max $2.87.
Current price is $0.42 and market cap is $5.84M. The stock rank is 5007.
RSI14 is 40 (neutral). SMA50 is $0.5463 and SMA200 is $1.50. Support is at $0.391 and resistance at $0.614. The 30-day range is $0.3069 to $0.5747, and annualized volatility is 90%.
Vivos Therapeutics, Inc. Community Discussion
0Share your Vivos Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.